Skip to main content

ASCIA News

  • National Allergy Priorities for Research
      The National Allergy Centre of Excellence is Setting National Allergy Priorities for Research (SNAPR), to help make sure future allergy research addresses the issues that matter most to people living with allergies, their families and healthcare providers. What's involved? Complete the...
  • Allergy and Immunology Foundation of Australia (AIFA) 2025 grant round is now open  
    It is a pleasure to announce that Expressions of Interest (EOIs) are invited from ASCIA members for AIFA grants that support clinically important research into allergy and other immune diseases. EOIs are due by midnight on 30th May 2024 and the application form is on the...
  • ASCIA Immunodeficiency Strategy - April 2025 update
    To coincide with World PI Week (22 - 29 April 2025) and World Immunology Day on 29 April 2025, ASCIA is proud to announce that a new ASCIA Project Officer, Vargha Khosh Aein, has been appointed, to progress implementation of the ASCIA Immunodeficiency Strategy for...
  • New international consensus report on anaphylaxis
    A new international consensus report on anaphylaxis has been released by the Global Allergy and Asthma Excellence Network (GA2LEN) and published open access online in the Journal of Allergy and Clinical Immunology.  The report was developed by an international panel of 46...
  • National Allergy Council projects allocated to ASCIA - March 2025 update
    The National Allergy Council is a partnership between the Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA), funded by the Australian Government Department of Health and Aged Care to implement the National Allergy...
  • New ARISE allergic rhinitis (hay fever) trial
    General practices and allergy clinics across Australia are invited to take part in a new clinical trial aiming to improve the lives of young people with hay fever, our country’s most common allergic disease.  Recruitment sites in every state and territory have partnered...
  • Shingrix vaccine to prevent shingles - Update
    Shingrix®  is a varicella zoster virus recombinant vaccine that can provide protection from herpes zoster (shingles) and post-herpetic neuralgia (long-term nerve pain): Advice for Health Care Professionals with regards to patient eligibility for the Shingles NIP can now be...
  • ASCIA anaphylaxis e-training approved by RACGP, ACCRM and PSA
    ASCIA online courses provide accessible, consistent and evidence-based training in anaphylaxis, allergy and immune deficiencies. The updated 2025 version of ASCIA anaphylaxis e-training for health professionals has been approved as a CPD activity by the following...
ASCIA Member Login

Site last updated: 9 May 2025
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...